The Effect of Conflict of Interest on Biomedical Research and Clinical Practice Guidelines: Can We Trust the Evidence in Evidence-Based Medicine?

References

1. ↵
   Andreoli TE. The undermining of academic medicine. Academe 1999; 6: 32–37. Available from: http://www.aaup.org/publications/Academe/1999/99nd/ND99Andr.htm, accessed 06/14/05.
2. ↵
   Krimsky S. Science in the private interest. Lanham (MD): Rowman and Littlefield; 2003.
3. ↵
   Culliton BJ. The academic-industrial complex. Science 1982; 216: 960–2.

   OpenUrlFREE Full Text
4. ↵
   Bok D. Universities in the marketplace. Princeton (NJ): Princeton University Press; 2003.
5. ↵
   Dramatic growth of research and development (http://www.phrma.org/publications/publications/profile02/2003%20CHAPTER%202.pdf accessed 6/14/05). In: Pharmaceutical Research and Manufacturers of America, editor. Pharmaceutical Industry Profile 2003. Washington (DC): Pharmaceutical Research and Manufacturers of America; 2003.
6. ↵
   The House of Commons Health Committee, The Influence of the Pharmaceutical Industry, Volume 1. April 5, 2005, p. 55. Available from: http://www.parliament.the-stationery-office.co.uk/pa/cm200405/cmselect/cmhealth/42/42.pdf, accessed 6/08/05.
7. ↵
   Petersen M. Madison Ave. has growing role in the business of drug research. New York Times, November 22, 2002.
8. ↵
   Bodenheimer T. Uneasy alliance–clinical investigators and the pharmaceutical industry. N Engl J Med 2000; 342: 1539–44.

   OpenUrlCrossRefPubMedWeb of Science
9. ↵
   Als-Nielsen B, Chen W, Gluud C, Kjaergard LL. Association of funding and conclusions in randomized drug trials: a reflection of treatment effect or adverse events? JAMA 2003; 290: 921–8.

   OpenUrlCrossRefPubMedWeb of Science
10. ↵
    Schulman KA, Seils DM, Timbie JW, et al. A national survey of provisions in clinical-trial agreements between medical schools and industry sponsors. N Engl J Med 2002; 347: 1335–41.

    OpenUrlCrossRefPubMedWeb of Science
11. ↵
    Effect of user fees on drug approval times, withdrawals, and other agency activities. United States General Accounting Office, September, 2002, p. 9. Available from: http://www.gao.gov/new.items/d02958.pdf, accessed 6/27/05.
12. ↵
    Willman D. Risk was known as FDA OKd fatal drug. Los Angeles Times. March 11, 2001.
13. ↵
    American College of Physicians. Guidelines for Counseling Postmenopausal Women About Preventive Hormone Therapy. Ann Intern Med 1992; 117: 1038–41.
14. ↵
    FDA Arthritis Advisory Committee Briefing Information, February 8, 2001. Available from: http://www.fda.gov/ohrms/dockets/ac/01/briefing/3677b1.htm, accessed 6/27/05.
15. ↵
    FDA Arthritis Advisory Committee Briefing Information, February 7, 2001. Available from: http://www.fda.gov/ohrms/dockets/ac/01/briefing/3677b1.htm, accessed 6/27/05.
16. ↵
    Witter J. FDA Advisory Committee Briefing Document, Celebrex capsules, Medical Officer Review, February 7, 2001. Available from: http://www.fda.gov/ohrms/dockets/ac/01/briefing/3677b1_03_med.doc, accessed 6/28/05.
17. ↵
    Villalba ML. FDA Advisory Committee Briefing Document, Vioxx gastrointestinal safety, February 8, 2001. Available from: http://www.fda.gov/ohrms/dockets/ac/01/briefing/3677b2_03_med.pdf, accessed 9/16/2001.
18. ↵
    Li Q. FDA Advisory Committee Briefing Document, Statistical Review, February 8, 2001. Available from: http://www.fda.gov/ohrms/dockets/ac/01/briefing/3677b2_04_stats.doc, accessed 6/27/05.
19. ↵
    FDA Medical Officer’s Gastroenterology Advisory Committee Briefing Document, February 7, 2001. Available from: http://www.fda.gov/ohrms/dockets/ac/01/briefing/3677b1_05_gi.doc, accessed 6/28/05.
20. ↵
    Silverstein FE, Faich G, Goldstein JL, et al. Gastrointestinal toxicity with celecoxib vs nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis: The CLASS study: a randomized controlled trial. JAMA 2000; 284: 1247–55.

    OpenUrlCrossRefPubMedWeb of Science
21. ↵
    Okie S. Missing data on Celebrex full study altered picture of drug. Washington Post, August 5, 2001; A11.
22. ↵
    Bombardier C, Laine L, Reicin A, Shapiro D, Burgos-Vargas R, et al. Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. The VIGOR study group. N Engl J Med 2000; 343: 1520–8.

    OpenUrlCrossRefPubMedWeb of Science
23. ↵
    FitzGerald GA, Patrono C. The coxibs, selective inhibitors of cyclooxygenase-2. N Engl J Med 2001; 345: 433–42.

    OpenUrlCrossRefPubMedWeb of Science
24. ↵
    American College of Rheumatology Subcommittee on Osteoarthritis Guidelines. Recommendations for the medical management of osteoarthritis of the hip and knee: 2000 update. Arthritis Rheum 2000; 43: 1905–15.

    OpenUrlCrossRefPubMedWeb of Science
25. ↵
    National Guideline Clearinghouse. Available from: http://www.guidelines.gov/
26. ↵
    Choudhry NK, Stelfox HT, Detsky AS. Relationships between authors of clinical practice guidelines and the pharmaceutical industry. JAMA 2002; 287: 612–7.

    OpenUrlCrossRefPubMedWeb of Science
27. ↵
    Grundy SM, Cleeman JI, Merz CN, et al. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines. Circulation 2004; 110: 227–39.

    OpenUrlAbstract/FREE Full Text
28. ↵
    National Cholesterol Education Program. Third Report of the Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). Available from: http://www.nhlbi.nih.gov/guidelines/cholesterol/atp3upd04_disclose.htm accessed 6/14/05. Bethesda (MD): National Heart, Lung, and Blood Institute, 2004.
29. ↵
    Willman D. The National Institutes of Health: public servant or private marketer? Los Angeles Times, December 22, 2004;1.
30. ↵
    American Heart Association. American Heart Association Annual Report 2004: Learn and Live. Available from: http://www.americanheart.org/downloadable/heart/1106163695297FINAL%20Annual04%20ASA%20Update.pdf, accessed 6/14/05. Dallas (TX): American Heart Association, 2004.
31. ↵
    Arthritis Foundation, Arthritis Foundation Annual Report 2002: Think it’s just arthritis? The truth hurts. Available from: http://www.arthritis.org/resources/aboutus/Annual_Reports/2002/Annual%20Report.Final.pdf, accessed 6–14-05). Atlanta (GA): Arthritis Foundation, 2002.
32. ↵
    American Diabetes Association. American Diabetes Association Report 2004: rising to meet the challenge. Available from: http://www.diabetes.org/uedocuments/AnnualFINAL.pdf, accessed 6–14-05. Alexandria (VA): American Diabetes Association, 2005.
33. ↵
    Relman AS. Industry sponsorship of continuing medical education—reply. JAMA 2003; 290: 1150.

    OpenUrlCrossRefPubMed
34. ↵
    2005 Match Information Sheet, American Academy of Family Practice. Available from: http://www.aafp.org/match/graph05.html, accessed 6/27/05.
35. ↵
    Kravitz RL, Duan N, Braslow J. Evidence-based medicine, heterogeneity of treatment effects, and the trouble with averages. Milbank Q 2004; 82: 661–87.

    OpenUrlCrossRefPubMedWeb of Science
36. Rothwell PM. External validity of randomised controlled trials: to whom do the results of this trial apply? Lancet 2005; 365: 82–93.

    OpenUrlCrossRefPubMedWeb of Science
37. Steinberg EP, Luce BR. Evidence based? Caveat emptor! Health Aff 2005; 24: 80–92.

    OpenUrlAbstract/FREE Full Text